First-line immune checkpoint inhibitor plus anti-angiogenic therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials
Background The meta-analysis assesses the efficacy and safety of first-line immune checkpoint inhibitors (ICIs) plus anti-angiogenic therapies versus sunitinib in advanced or metastatic renal cell carcinoma (RCC). The analysis places focus on differential benefits across International Metastatic RCC Database Consortium...